This 2023 focused update provides guidelines on the indications and management of mechanical circulatory support devices (PCPS, ECMO, IMPELLA) for severe heart failure.
Answers are grounded in this paper and cite their sources.
Supports expanded PCPS/ECMO use in severe HF; extends prior guidelines with recent survival data.
Mechanical circulatory support (MCS) plays a significant role as a therapeutic option for severe heart failure, and its outcomes have been improving due to advancements in devices and management techniques. In particular, percutaneous cardiopulmonary support (PCPS) and extracorporeal membrane oxygenation (ECMO) have contributed to both expanding the range of conditions that can be treated and improving survival rates through the accumulation of knowledge on the clinical introduction, indications, and management of these novel devices in recent years.
No takes yet. Share an insight, caveat, or question.
Nishimura et al. (2024) conducted a review in Severe heart failure. Mechanical circulatory support (PCPS/ECMO/IMPELLA) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: